EndoStream Medical Overview
EndoStream is dedicated to developing safe and effective solutions that significantly improve clinical outcomes for patients suffering from brain aneurysms. The company's aneurysm devices, utilizes self-conforming scaffolds that adapt to an aneurysm’s unique shape and provide maximal neck metal coverage. EndoStream developed Nautilus, a-traumatic, self-conforming intrasaccular flow diverter maximizing neck coverage and enhancing coil stability, to optimize intrasaccular thrombosis and enable progressive occlusion.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Japan's Kaneka buys Israeli co EndoStream Medical
EndoStream Medical Ltd., an Or Akiva-based medical device company, has been acquired by Japans Kaneka Corporation, which now owns 96.8% of the companys shares. EndoStream is known for developing the Nautilus device for aneurysm treatment, which has received EU regulatory approval and is expected to launch in the US and Japan in the coming years. Although financial details of the acquisition were not disclosed, industry sources estimate the deal to be worth at least $100 million. The acquisition is expected to enhance Kanekas capabilities in developing cerebrovascular treatment devices, with a sales target of over $120 million by 2030. Peregrine Ventures, the sole venture capital fund involved, stands as a significant beneficiary of this acquisition.
Acquired-byInvestment
growth-positive
The Or Akiva-based medical device company is developing the Nautilus device for aneurysm treatment.
EndoStream Medical Ltd., an Or Akiva-based medical device company, has been acquired by Japans Kaneka Corporation, which now holds 96.8% of its shares. EndoStream is known for developing the Nautilus device for aneurysm treatment, which has received EU regulatory approval and is expected to launch in the US and Japan in the coming years. The acquisition is valued at over $100 million, although exact financial details were not disclosed. The acquisition is expected to facilitate the joint development and manufacturing of new medical devices for cerebrovascular treatment, with Kaneka aiming for significant sales growth by 2030. Peregrine Ventures and a group of American neurosurgeons were key investors in EndoStream.
Acquired-by
growth-positive
EndoStream enrols first patient in trial of Nautilus Intrasaccular System
EndoStream Medical has enrolled the first patient in a clinical trial for its Nautilus Intrasaccular System, a revolutionary technology for the treatment of cerebral aneurysms. The patient was treated at The Mount Sinai Hospital in New York. The Nautilus System increases neck coverage and improves coil stability, optimizing intrasaccular thrombosis. The patient also received treatment with Kaneka i-ED coils, which have demonstrated excellent aneurysm occlusion rates. The EndoStream system promotes intrasaccular thrombosis and endothelial remodeling while eliminating the need for antiplatelet therapy. The Nautilus Intrasaccular System is CE marked and approved for sale in Europe, but not yet in the US.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.9M |
| Last funding | $1.89M |
| Stage | Acquired |
| Rounds | 2 |
| Investors | 5 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | endostream.com |
Locations
Berkovich Street 4, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
